Genprex, Inc. (NASDAQ: GNPX) Genetics Sector Working with Big Pharma and Generating Big Potential

Genprex, Inc. (NASDAQ: GNPX) Genetics Sector Working with Big Pharma and Generating Big Potential

Genprex (GNPX) Pipeline Could Impact or Eradicate Cancer and Diabetes with Promising Gene Development

Possible short squeeze here. Since February, the company shares have consolidated, and we want to note that according to shortsqueeze.com there are 4.17M GNPX shares shorted or 12.3% of the public float. Now these traders are up pretty big following GNPX share price dropping from $7.70 to the current levels. We could see them covering these positions very soon, why wait and be greedy. Should the company announce a collab, licensing deal or positive data which could come at anytime they could quickly see those profits evaporate and end up in bulls pockets.

Genprex (GNPX) is a Small Cap Company in the Genetics Sector Working with Big Pharma and Generating Big Potential

“Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes”

Good day everyone,

We are updating our coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer and diabetes.

Current price $3.79 per share

Outstanding shares (est.) 43.2M

Shares in Float (est.) 33.7M

Insider ownership 17.4%

Institutional ownership 18.6%

We last issued a report on GNPX December 21st of 2020. At that time, the company shares were at $3.50 and gained 41% over two days. By February 8th, 2021 GNPX shares reached a high of $7.72/share. With the current share price, and new developments at the company we believe similar movements in the share price could come near term.

The company stock chart indicates that GNPX shares have fallen below their 50 DMA and 200 DMA of $4.55 and $4.07, respectively. The current RSI (14) is 40.56. These data can be indicators of oversold shares. The company’s stock performance this year, and the absence any adverse events, may indicate the potential for a large near-term gain.

Since February, the company shares have consolidated, and we want to note that according to shortsqueeze.com there are 4.17M GNPX shares shorted or 12.3% of the public float.

The leading-edge technology offered by GNPX, in the field of genetics, is being watched by many in the biopharma sector, not only because of the genes there are developing, but because of their proprietary gene delivery system. Companies such as Astra Zeneca, Merck, and Genentech have programs working with GNPX.

Inclusion in the Russell 3000 Index has increased Genprex’s visibility among institutional investors, money managers, and index funds. On February 5, 2021 Blackrock, Inc. increased its holdings in GNPX to 4.9% of the outstanding shares (marketbeat.com).

GNPXs lead product candidate is REQORSA (Tusc2 gene)

REQORSA™ immunogene therapy for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

In a recent development announced April 12th, Genprex collaborators reported positive preclinical data for REQORSA™

Rodney Varner, President and Chief Executive Officer of Genprex said. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

Diabetes gene therapy, GPX-002 (Recent news April 20th, 2021)
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes

The company has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to cure Type 1 and Type 2 diabetes. The gene therapy, developed at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, works by reprogramming beta cells in the pancreas to restore their function, allowing them to replenish insulin levels.

Considerations:
Tiny float
Trading 50% off its February high
High insider and institutional ownership
Jan-26-21 National Securities Buy $7.00/share target.

Stay tuned for our full report on GNPX with more information on their pipeline.

Together we’re strong,
The Traders News Group

 

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty one thousand dollars cash via bank wire for our distributed opinions this week on gnpx. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.